| 100019-9 | ALK gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100020-7 | GNA11 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100021-5 | GNAQ gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100022-3 | IDH1 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100023-1 | IDH2 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100024-9 | SETBP1 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100025-6 | SRSF2 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100026-4 | MET gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100027-2 | SMAD4 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100028-0 | FBXW7 gene mutations found or Tissue (Blood, molecular genetics method nominal) |
| 100029-8 | Cancer related multigene analysis cell-free DNA (molecular genetics method) |
| 100213-8 | Prostate cancer multigene analysis or Tissue (Blood, molecular genetics method) |
| 100305-2 | IDH1 gene exon 4 targeted mutation analysis or Marrow (Blood, qualitative, molecular genetics method) |
| 100306-0 | IDH2 gene exon 4 targeted mutation analysis or Marrow (Blood, qualitative, molecular genetics method) |
| 100663-4 | TPMT gene c.460G>A and c.719A>G (Blood, qualitative, molecular genetics method) |
| 100664-2 | NUDT15 gene c.50_55dup and c.415C>T (Blood, qualitative, molecular genetics method) |
| 100665-9 | NUDT15 gene c.415C>T (Blood, qualitative, molecular genetics method) |
| 100666-7 | NUDT15 gene c.416G>A (Blood, qualitative, molecular genetics method) |
| 100667-5 | NUDT15 gene c.52G>A (Blood, qualitative, molecular genetics method) |
| 100668-3 | NUDT15 gene c.50_55dup (Blood, qualitative, molecular genetics method) |
| 100669-1 | NUDT15 gene c.50_55del (Blood, qualitative, molecular genetics method) |
| 100694-9 | SMN1 gene silent carrier analysis or Tissue (Blood, qualitative, molecular genetics method) |
| 100695-6 | Genetic disease analysis overall carrier interpretation or Tissue (Blood, molecular genetics method narrative) |
| 100696-4 | CTNS related multigene analysis in Bodyfluid and Serum or Plasma (molecular genetics method nominal) |
| 100717-8 | FCGR3A gene.p.Phe176Val or Tissue (Blood, qualitative, molecular genetics method) |
| 100761-6 | PALB2 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 100762-4 | HBA2 gene.c.377T>C (Blood, qualitative, molecular genetics method) |
| 100864-8 | Giardia lamblia bg gene in Specimen (molecular genetics method) |
| 100868-9 | Cryptosporidium sp 18S-LC2 rRNA in Specimen (molecular genetics method) |
| 100869-7 | Cryptosporidium gp60 gene in Specimen (molecular genetics method) |
| 100870-5 | Cryptosporidium 18S rRNA in Specimen (molecular genetics method) |
| 100871-3 | Giardia lamblia gdh gene in Specimen (molecular genetics method) |
| 100873-9 | Giardia lamblia tpi gene in Specimen (molecular genetics method) |
| 101123-8 | Bacterial carbapenem resistance blaIMI gene (qualitative, molecular method) |
| 101124-6 | Bacterial carbapenem resistance blaIMI+blaNMC genes (qualitative, molecular method) |
| 101125-3 | Bacterial carbapenem resistance blaOXA-235-like gene (qualitative, molecular method) |
| 101126-1 | Bacterial carbapenem resistance blaOXA-24+blaOXA-40 gene (qualitative, molecular method) |
| 101127-9 | Bacterial carbapenem resistance blaSIM gene (qualitative, molecular method) |
| 101141-0 | NAT2 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101142-8 | NAT2 gene allele or Tissue (Blood, molecular genetics method nominal) |
| 101143-6 | NAT2 gene product metabolic activity interpretation or Tissue Qualitative (Blood, qualitative, molecular genetics method) |
| 101152-7 | Mitochondria whole genome analysis or Tissue (Blood, molecular genetics method) |
| 101377-0 | inv(16)(p13.1;q22.1)(MYH11,CBFB) fusion transcript or Marrow (Blood, molecular genetics method) |
| 101381-2 | BAP1 gene deletion+duplication and full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101382-0 | FH gene deletion+duplication and full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101385-3 | NF1 gene deletion+duplication and full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101386-1 | RET gene deletion+duplication and full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101387-9 | HBA1 and HBA2 gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101388-7 | GP1BB full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101389-5 | GP1BA gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101390-3 | GP9 gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101391-1 | PAH gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101392-9 | ADA gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101393-7 | CLCN7 gene full mutation analysis or Tissue (Blood, molecular genetics method) |
| 101394-5 | Sex in Embryo (molecular genetics method) |
| 101395-2 | Translocation analysis in Embryo (molecular genetics method) |
| 101396-0 | Preimplantation multigene analysis in Embryo (molecular genetics method) |
| 101469-5 | HBA1+2 gene FIL deletion (Blood, qualitative, molecular genetics method) |
| 101470-3 | HBA1+2 gene THAI deletion (Blood, qualitative, molecular genetics method) |
| 101538-7 | SMA residual risk (Blood, molecular genetics method narrative) |
| 101545-2 | FCGR3A gene.p.Phe158 (Blood, molecular genetics method nominal) |
| 101546-0 | FCGR3A gene.p.Val158 (Blood, molecular genetics method nominal) |
| 101576-7 | Bacterial gyrB gene drug resistance mutation (molecular method) |
| 101590-8 | VKORC1 gene allele or Tissue (Blood, molecular genetics method nominal) |
| 101633-6 | MT-RNR1 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101636-9 | TCRB gene and TCRG gene rearrangements (Bone Marrow, molecular genetics method) |
| 101637-7 | TCRB gene and TCRG gene rearrangements or Tissue (Blood, molecular genetics method) |
| 101638-5 | TCRB gene and TCRG gene rearrangements in Specimen (molecular genetics method) |
| 101671-6 | Hereditary Wilms tumor multigene analysis or Tissue (Blood, molecular genetics method) |
| 101785-4 | CYP2C Cluster Allele or Tissue (Blood, molecular genetics method) |
| 101820-9 | Preimplantation targeted mutation analysis in Embryo (molecular genetics method) |
| 101952-0 | MTTP gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101953-8 | COL4A3 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101954-6 | SLC35A3 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101955-3 | DNAI1 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101956-1 | COQ4 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101957-9 | RTEL1 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101958-7 | ADAMTS2 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101959-5 | TCIRG1 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101960-3 | PEX2 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101961-1 | PHGDH gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101962-9 | DHDDS gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101963-7 | SLC1A4 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101964-5 | HPS3 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 101965-2 | NDUFAF5 gene targeted mutation analysis or Tissue (Blood, molecular genetics method) |
| 102038-7 | ROS proto-oncogene 1 mutations found or Tissue (Blood, molecular genetics method nominal) |
| 102039-5 | MET gene amplification or Tissue (Blood, molgen) |
| 102091-6 | HBA1 and HBA2 gene full mutation analysis or Chorionic villus sample (Amniotic Fluid, molecular genetics method) |
| 102113-8 | Mixed chimerism post SCT transplantation in Peripheral blood (molecular genetics method) |
| 102116-1 | ESR1 gene mutation panel - Tissue (molecular genetics method) |
| 102117-9 | Gastrointestinal stromal tumor multigene mutation panel - Tissue (molecular genetics method) |
| 102118-7 | Rhabdomyolysis and Metabolic myopathy multigene panel - Blood or Tissue (molecular genetics method) |
| 102119-5 | Skeletal muscle channelopathy multigene panel - Blood or Tissue (molecular genetics method) |
| 103141-8 | Staphylococcus aureus MLVA complex in Isolate or Specimen (molecular genetics method) |
| 103143-4 | Genetic disease DNA and RNA analysis or Tissue (Blood, qualitative, molecular genetics method) |
| 103156-6 | CD3 cells recipient derived/Cells.CD3 (Blood, molecular genetics method --post bone marrow transplant) |
| 103556-7 | PLA2G7 and PLAC8 gene expression level (Blood, molecular genetics method) |
| 103557-5 | SARS-CoV-2 (COVID-19) Mpro gene mutation detected in Specimen (molecular genetics method nominal) |
| 103601-1 | Staphylococcus aureus MLVA type in Isolate or Specimen (molecular genetics method) |
| 103677-1 | HMEP-Hemiplegic migraine multigene analysis or Tissue (Blood, molecular genetics method) |